Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.24 USD
0.00 (0.84%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.24 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Brainstorm Cell Therapeutics Inc. [BCLI]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-Rated Reports Q1 Burning $5M a QTR, $22M in Cash, but Where is this Going?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-Rated Reports Q3 Our Comments are Unchanged: Does NurOwn Work?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-Rated - Reports the Quarter - Our Comments are Unchanged from the Prior QTR:Company has Cash, but Signal to Noise Ratio is High
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-Rated Reports the Quarter - Company has Cash, but Signal to Noise Ratio is High
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-Rated- Progressive Multiple Sclerosis?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral-FDA Says You Haven''t Met the Threshold
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Neutral - A High Placebo Response in ALS Causes a Lack of Significance Between the Active Arm 35% vs. Placebo 28%. Is There a Path Forward?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
BUY -Brainstorm Secures Manufacturing for NurOwn
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
BUY - On Track in ALS For Data by Year''s End, Rolling our Valuation Forward - Raising Price Target from $14.00 to $25.00
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
BUY On Track in ALS For Data by Year''s End
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Brainstorm Cell Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
NurOwn Published in the Journal of Neurology
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J